NCT01975818View on ClinicalTrials.gov

Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

PHASE2CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

October 28, 2013

Primary Completion Date

October 23, 2015

Study Completion Date

December 15, 2015

Conditions
AnemiaRenal Insufficiency, Chronic
Interventions
DRUG

Molidustat (BAY 85-3934)

Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets

BIOLOGICAL

Epoetin alfa/beta

Trial Locations (35)

11212

Brooklyn

11365

Fresh Meadows

14215

Buffalo

33028

Pembroke Pines

34652

New Port Richey

43615

Toledo

45206

Cincinnati

48202

Detroit

48236

Detroit

63141

Creve Coeur

73116

Oklahoma City

75050

Grand Prairie

76063

Mansfield

76104

Fort Worth

76105

Fort Worth

76164

Fort Worth

77004

Houston

77091

Houston

78215

San Antonio

78229

San Antonio

90025

Los Angeles

90262

Lynwood

90602

Whittier

90606

Whittier

90813

Long Beach

91324

Northridge

91702

Azusa

91773

San Dimas

07724

Eatontown

37212-8150

Nashville

050-0083

Muroran

670-0947

Himeji

511-0061

Kuwana

607-8116

Kyoto

388-8004

Nagano

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01975818 - Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 | Biotech Hunter | Biotech Hunter